Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HASPIN | Q8TF76 | 4/20 | 0.86 |
| ▸ | DYRK1A | Q13627 | 17/20 | 0.86 |
| ▸ | HTR2A | P28223 | 1/20 | 0.76 |
| ▸ | HTR2C | P28335 | 1/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17517505 | 1.00 | HASPIN (0.86) | HASPINDYRK1AHTR2AHTR2C | |
| SCHEMBL17502361 | 1.00 | HASPIN (0.86) | HASPINDYRK1AHTR2AHTR2C | |
| SCHEMBL17502363 | 1.00 | HASPIN (0.86) | HASPINDYRK1AHTR2AHTR2C | |
| SCHEMBL13875060 | 0.99 | HASPIN (0.88) | HASPINDYRK1AHTR2AHTR2C | |
| SCHEMBL17517503 | 0.96 | DYRK1A (0.88) | HASPINDYRK1AHTR2AHTR2C | |
| SCHEMBL17102931 | 0.95 | DYRK1A (0.91) | HASPINDYRK1AHTR2AHTR2C | |
| SCHEMBL17102919 | 0.95 | DYRK1A (0.91) | HASPINDYRK1AHTR2AHTR2C | |
| SCHEMBL17102936 | 0.95 | DYRK1A (0.91) | HASPINDYRK1AHTR2AHTR2C | |
| SCHEMBL17102957 | 0.94 | DYRK1A (0.93) | HASPINDYRK1AHTR2AHTR2C | |
| SCHEMBL20340616 | 0.93 | DYRK1A (0.88) | HASPINDYRK1AHTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10011614-B2 | Bis-β-carboline compound and preparation method, pharmaceutical composition and use thereof | XINJIANG HUASHIDAN PHARMACEUTICAL RESEARCH CO., LTD (CN) | 2018-07-03 | — | — | US | disclosed |
| US-10011614-B2 | Bis-β-carboline compound and preparation method, pharmaceutical composition and use thereof | XINJIANG HUASHIDAN PHARMACEUTICAL RESEARCH CO., LTD (CN) | 2018-07-03 | — | — | US | disclosed |
| US-9433592-B2 | Pharmaceutical or veterinary antiviral compositions | UNIVERSITE CLAUDE BERNARD LYON 1 (FR) | 2016-09-06 | — | — | US | disclosed |
| US-20160039845-A1 | BIS-B-CARBOLINE COMPOUND AND PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | XINJIANG HUASHIDAN PHARMACEUTICAL RESEARCH CO., LTD (CN) | 2016-02-11 | — | — | US | disclosed |
| US-20160039845-A1 | BIS-B-CARBOLINE COMPOUND AND PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | XINJIANG HUASHIDAN PHARMACEUTICAL RESEARCH CO., LTD (CN) | 2016-02-11 | — | — | US | disclosed |
| US-20130012502-A1 | Pharmaceutical or Veterinary Antiviral Compositions | HOSPICES CIVILS DE LYON (FR) | 2013-01-10 | — | — | US | disclosed |
| WO-2011069990-A1 | PHARMACEUTICAL OR VETERINARY ANTIVIRAL COMPOSITIONS | UNIVERSITE CLAUDE BERNARD LYON 1 (FR) | 2011-06-16 | — | — | WO | disclosed |
| EP-2050747-A1 | Dimers of harmol or of its derivatives and uses thereof | BioAlliance Pharma (FR) | 2009-04-22 | — | — | EP | disclosed |
| WO-2009047298-A2 | DIMERS OF HARMOL OR OF ITS DERIVATIVES AND USES THEREOF | BIOALLIANCE PHARMA (FR) | 2009-04-16 | — | — | WO | disclosed |
| WO-2009047298-A2 | DIMERS OF HARMOL OR OF ITS DERIVATIVES AND USES THEREOF | BIOALLIANCE PHARMA (FR) | 2009-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160039845-A1 | BIS-B-CARBOLINE COMPOUND AND PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | BRCA1, CA7, DCK | HASPIN 872/4885DYRK1A 2258/4885HTR2A 3190/4885 |
| US-10011614-B2 | Bis-β-carboline compound and preparation method, pharmaceutical composition and use thereof | BRCA1, CA7, DCK | HASPIN 933/4885DYRK1A 2229/4885HTR2A 3333/4885 |
| US-20130012502-A1 | Pharmaceutical or Veterinary Antiviral Compositions | PIGS, ZC3HAV1, PRNP | HASPIN 2105/4885DYRK1A 4754/4885HTR2A 3725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.